Younossi, Z. M. et al. conducted an extensive systematic review detailing the global epidemiology of nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), revealing critical insights into the prevalence and risk factors associated with these conditions. The findings were published in Hepatology 77, 1335–1347 (2023).
Rinella, M. E. et al. have established a multisociety Delphi consensus statement aimed at standardizing new nomenclature surrounding fatty liver disease, making strides in the field of hepatology by providing clarity and aiding in more effective management practices. The study was published in J. Hepatol. 79, 1542–1556 (2023).
Sanyal, A. J. et al. conducted a groundbreaking prospective study analyzing the health outcomes of adults suffering from nonalcoholic fatty liver disease, contributing valuable data necessary for informed clinical decision-making regarding patient management. The results were shared in N. Engl. J. Med. 385, 1559–1569 (2021).
In a historic move, the FDA recently approved the first treatment targeting patients afflicted with liver scarring attributed to fatty liver disease. This development marks a significant advancement in the therapeutic landscape for those suffering from this condition. FDA (2024).
Harrison, S. A. et al. reported the results of a phase 3, randomized, controlled trial evaluating the efficacy of resmetirom in patients suffering from NASH with liver fibrosis, providing critical data essential for future treatment paradigms. The findings were published in N. Engl. J. Med. 390, 497–509 (2024).
Esteemed organizations such as the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) have collaboratively published Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD), thereby providing essential frameworks for clinical practice. These guidelines were featured in J. Hepatol. 81, 492–542 (2024).
Allen, A. M. and colleagues, including Younossi, Z. M., Diehl, A. M., Charlton, M. R., and Lazarus, J. V., explored prospects for advancing the MASH field, presenting a comprehensive overview of potential pathways for future research in the domain of liver-related diseases. This work appeared in Nat. Rev. Gastroenterol. Hepatol. 21, 726–738 (2024).
Here are the references formatted in a standard citation style:
1. Rinella, M.E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *J. Hepatol.* **79**, 1542–1556 (2023). doi:10.1016/j.jhep.2023.06.003. [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20multisociety%20Delphi%20consensus%20statement%20on%20new%20fatty%20liver%20disease%20nomenclature&journal=J.%20Hepatol.&doi=10.1016%2Fj.jhep.2023.06.003&volume=79&pages=1542-1556&publication_year=2023&author=Rinella%2CME).
2. Sanyal, A.J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *N. Engl. J. Med.* **385**, 1559–1569 (2021). doi:10.1056/NEJMoa2029349. [Article](https://doi.org/10.1056%2FNEJMoa2029349) | [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34670043) | [Google Scholar](http://scholar.google.com/scholar_lookup?&title=Prospective%20study%20of%20outcomes%20in%20adults%20with%20nonalcoholic%20fatty%20liver%20disease&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2029349&volume=385&pages=1559-1569&publication_year=2021&author=Sanyal%2CAJ).
3. FDA. FDA approves first treatment for liver scarring due to fatty liver disease. (2024).
4. Harrison, S.A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N. Engl. J. Med.* **390**, 497–509 (2024). doi:10.1056/NEJMoa2309000. [Article](https://doi.org/10.1056%2FNEJMoa2309000) | [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38324483) | [Google Scholar](http://scholar.google.com/scholar_lookup?&title=A%20phase%203%2C%20randomized%2C%20controlled%20trial%20of%20resmetirom%20in%20NASH%20with%20liver%20fibrosis&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2309000&volume=390&pages=497-509&publication_year=2024&author=Harrison%2CSA).
5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J. Hepatol.* **81**, 492–542 (2024).
6. Allen, A.M. et al. [Provide full citation for the study including title, journal, volume, pages, year, etc., as the text cuts off here].
Please provide the missing information for the last reference if you would like it completed.
